BIOARCTIC AB

BioArctic AB (publ) is a Swedish research-based biopharmaceutical company specializing in disease-modifying treatments for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS. Founded in 2003 by Professor Lars Lannfelt and Dr. Pär Gellerfors, it originated from groundbreaking discoveries like the Swedish and Arctic mutations explaining amyloid-beta’s role in Alzheimer’s. The company is renowned as the originator of lecanemab (Leqembi®), the world’s first approved drug proven to slow progression and reduce cognitive decline in early Alzheimer’s, developed in collaboration with Eisai. BioArctic maintains a broad portfolio of 15 research projects, leveraging proprietary technologies including selective antibodies against misfolded proteins and the innovative BrainTransporter™ platform, which enhances antibody transport across the blood-brain barrier for higher brain concentrations. This technology addresses key challenges in central nervous system drug delivery. With 107 employees, significant partnerships like a USD 1.35 billion license deal with Bristol Myers Squibb, and preparations for Leqembi launch in the Nordic region, BioArctic plays a pivotal role in advancing therapies for unmet medical needs in neurodegenerative disorders, supported by 20 years of world-leading research.